Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 11/2017

01-11-2017 | Review Article

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs

Authors: Ipek Celikyurt, Christoph R. Meier, Michael Kühne, Beat Schaer

Published in: Drug Safety | Issue 11/2017

Login to get access

Abstract

Direct oral anticoagulants (DOACs) are novel direct-acting medications that are selective for either thrombin or activated factor X. Due to their obvious benefits for patients (fewer interactions, broader therapeutic window, etc.), they are increasingly used as an alternative to warfarin, phenprocoumon, or acenocoumarol. One of the major indications for use of DOACs is stroke prevention in patients with atrial fibrillation (AF). However, interactions still exist, especially in combination with antiarrhythmic drugs (AADs), which are frequently given to AF patients for rhythm or rate control. These interactions are due to the cytochrome P450 system and the P-glycoprotein (permeability glycoprotein or multidrug resistance protein) transport system. For some combinations, dose reduction of the DOAC is recommended and in some cases contraindications exist. In addition, impairment in renal and hepatic function plays an important role in this context. However, compared with pure interactions where data are quite convincing, the latter topic has been studied only rudimentarily. This review summarizes the literature on the safety and interactions of AADs when used with DOACs [dabigatran (a direct inhibitor of factor IIa) and rivaroxaban, apixaban and edoxaban (direct inhibitors of factor Xa)] and the impact of renal and hepatic impairment.
Literature
1.
Reiffel JA, Weitz JI, Reilly P, Kaminskas E, Sarich T, Sager P, et al. DOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: a cardiac safety research consortium think tank. Cardiac safety research consortium presenters and participants. Am Heart J. 2016;177:74–86.CrossRefPubMed
2.
Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015;35(5):1056–65.CrossRefPubMed
3.
Kundu A, Sardar P, Chatterjee S, Aronow WS, Owan T, Ryan JJ. Minimizing the risk of bleeding with DOACs in the elderly. Drugs Aging. 2016;33(7):491–500.CrossRefPubMed
4.
Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;24(11):967–77.CrossRef
5.
Gottlieb M, Khishfe B. Idarucizumab for the reversal of dabigatran. Ann Emerg Med. 2017;69(5):554–8.CrossRefPubMed
6.
Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326–43.CrossRefPubMed
7.
Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64(7):956–67.CrossRefPubMed
8.
9.
10.
Abrams PJ, Emerson CR. Rivaroxaban: a novel, oral, direct factor Xa inhibitor. Pharmacotherapy. 2009;29(2):167–81.CrossRefPubMed
11.
Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated FactorXa. Curr Opin Investig Drugs. 2008;9(9):1020–33.PubMed
12.
Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf. 2000;23(6):509–32.CrossRefPubMed
13.
14.
Gong I. Pharmacogenetics of oral anticoagulants and antiplatelets [PhD thesis]. London: the University of Western Ontario; 2013.
15.
Rodriguez I, Abernethy DR, Woosley RL. P-glycoprotein in clinical cardiology. Circulation. 1999;99(4):472–4.CrossRefPubMed
16.
Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 1999;99(4):552–7.CrossRefPubMed
17.
Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006;20(3):273–82.CrossRefPubMed
18.
Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein. Clin Pharmacol Drug Dev. 2014;3(3):194–201.CrossRefPubMed
19.
Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285–95.CrossRefPubMed
20.
21.
Kwong LM, Tong LM. Drug interactions with rivaroxaban following total joint replacement surgery. Ann Pharmacother. 2012;46(9):1232–8.CrossRefPubMed
22.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefPubMed
23.
Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, Schaefer O, et al. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers. Drug Metab Dispos. 2014;42(2):250–6.CrossRefPubMed
24.
Rybak I, Ehle M, Buckley L, Fanikos J. Efficacy and safety of novel anticoagulants compared with established agents. Ther Adv Hematol. 2011;2(3):175–95.CrossRefPubMedPubMedCentral
25.
26.
Stambler BS. A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. Int Arch Med. 2013;6(1):46.CrossRefPubMedPubMedCentral
27.
Voukalis C, Lip GY, Shantsila E. Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol. 2016;12(12):1445–61.CrossRefPubMed
28.
Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168–75.CrossRefPubMed
29.
Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatranetexilate (Pradaxa®) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75(4):1053–62.CrossRefPubMed
30.
Stangier J, Stähle H, Rathgen K, Roth W, Reseski K, Körnicke T. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol. 2012;52(2):243–50.CrossRefPubMed
31.
32.
Ahrens I, Peter K, Lip GY, Bode C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med. 2012;13(73):445–50.PubMed
33.
Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005;48(19):5900–8.CrossRefPubMed
34.
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114(22):2374–81.CrossRefPubMed
35.
Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47(11):1478–87.CrossRefPubMed
36.
37.
Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014;111(2):240–8.CrossRefPubMed
38.
Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, et al. ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541–50.CrossRefPubMed
39.
Stacy ZA, Call WB, Hartmann AP, Peters GL, Richter SK. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther. 2016;5(1):1–18.CrossRefPubMedPubMedCentral
40.
Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331–42.CrossRefPubMedPubMedCentral
41.
Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, et al. Hokusai-VTE Investigators. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-Venous Thromboembolism study—methodological implications for clinical trials. J Thromb Haemost. 2013;11(7):1287–94.CrossRefPubMed
42.
Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016;68(11):1169–78.CrossRefPubMed
43.
Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol. 2012;60(4):335–41.CrossRefPubMed
44.
Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Advisors: updated European Heart Rhythm Association practical guide on theuse of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Europace. 2015;17(10):1467–507.CrossRefPubMed
45.
Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol. 2016;13(1):36–47.CrossRefPubMed
46.
47.
Patel MR, Mahaffey KW, Garg J. New England Journal of Medicine 2011.
48.
Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet. 2007;46(12):985–96.CrossRefPubMed
49.
Anand AC, Chawla YK. Prescribing drugs for patients with liver disease. Natl Med J India. 1999;12(5):217–24.PubMed
50.
Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100(7):550–6.CrossRefPubMed
51.
Liakoni E, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of new oral anticoagulants (DOACs). Drug Saf. 2015;38(8):711–20.CrossRefPubMed
52.
Khoury T, Ayman AR, Cohen J, Daher S, Shmuel C, Mizrahi M. The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going. Digestion. 2016;93(2):149–59.CrossRefPubMed
Metadata
Title
Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs
Authors
Ipek Celikyurt
Christoph R. Meier
Michael Kühne
Beat Schaer
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 11/2017
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-017-0567-5

Other articles of this Issue 11/2017

Drug Safety 11/2017 Go to the issue

Original Research Article

Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System

Leading Article

Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury

Original Research Article

Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database

Original Research Article

Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case–Control Study in South Korea

Commentary

Pharmacovigilance Using Textual Data: The Need to Go Deeper and Wider into the Con(text)

Review Article

Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review